GSK 3039294

Drug Profile

GSK 3039294

Alternative Names: GSK-3039294

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Neuroprotectants
  • Mechanism of Action Serum amyloid P component inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyloidosis

Most Recent Events

  • 22 Nov 2017 GSK suspends patient enrolment in a phase I trial for Amyloidosis in United Kingdom (PO) (NCT02603172)
  • 20 Nov 2015 Preclinical trials in Amyloidosis in United Kingdom (PO) before November 2015
  • 20 Nov 2015 GSK plans a phase I trial for Amyloidosis in United Kingdom (PO) (NCT02603172)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top